Combined small-cell lung carcinoma

EQS-News: Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed

Retrieved on: 
Sunday, December 18, 2022
Acquisition, R, Sunlight, Pancreatic cancer, NYSE, Health, Advertising, AAPL, Safety, Cancer, Regeneron Pharmaceuticals, Tesla, McGill, COVID-19, Vaccine, General Hospital, Eli Lilly and Company, RNA transfection, Squamous cell carcinoma, Breast cancer, LLY, Apple, Growth, TSLA, Immune system, Research, University, Combined small-cell lung carcinoma, Patient, Drug resistance, PFE, COVID, Pharmaceutical industry, Pfizer

Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed

Key Points: 
  • Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed
    Protests have mounted in intensity across China in the past weeks, as more and more citizens become frustrated with the country’s radical “Zero-Covid” policies.
  • Sunshine Biopharma, Inc. (NASDAQ: SBFM) is a Canada-based pharmaceutical company combating COVID-19 through the development of SBFM-PL4, an antiviral treatment.
  • The company is confident that, in a Covid-19 vaccine market worth $13.6 billion , its drug candidate could provide a welcome solution.
  • Studies using non-transformed (normal) human cells (HMEC) have shown that K1.1 mRNA had little or no cytotoxic effects.

Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 8, 2022
SAN, GLOBE, Review, Forecasting, ESR1, ENA, Toxicity, Heel, Research, Fulvestrant, Securities Act of 1933, Fast track (FDA), R, News, Fast Track, Safety, U.S. Securities and Exchange Commission, CDK, Ribociclib, Securities Exchange Act of 1934, Pharmacokinetics, SERD, GAAP, Combined small-cell lung carcinoma, Patient, Woman, SECURE Act of 2019, Industry, FDA, Trial of the century, Pharmaceutical industry, Bank, G&A

Non-GAAP R&D expenses were $14.8 million for the quarter ended September 30, 2022, excluding $2.8 million of non-cash stock-based compensation expense.

Key Points: 
  • Non-GAAP R&D expenses were $14.8 million for the quarter ended September 30, 2022, excluding $2.8 million of non-cash stock-based compensation expense.
  • Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers.
  • We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance.
  • Except as required by law, Olema assumes no obligation to update these forward-looking statements or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

EQS-News: What Does Sunshine Biopharma’s Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?

Retrieved on: 
Monday, November 7, 2022
OBI Pharma, Inc., Health Canada, Growth, RNA transfection, Food, Ibuprofen, McGill, General Hospital, CAGR, Regulation of tobacco by the U.S. Food and Drug Administration, Squamous cell carcinoma, FDA, Breast, Safety, Metoprolol, Health, COVID-19, Patient, University, Metformin, Pancreatic cancer, Breast cancer, Viatris, Famotidine, Combined small-cell lung carcinoma, NASDAQ, Acquisition, Drug Price Competition and Patent Term Restoration Act, Sunlight, Advertising, News, Generic, Generic drug, Pharmaceutical industry, Fine chemical, Vaccine

What Does Sunshine Biopharmas Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?

Key Points: 
  • What Does Sunshine Biopharmas Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?
  • Nora Pharma is now a wholly owned subsidiary of Sunshine after the acquisition of its outstanding shares.
  • This acquisition allows Sunshine Biopharma to expand its operations into generic prescription drugs and biosimilars.
  • This acquisition gives Sunshine a solid position in the generic prescription drugs industry and brings us closer to our objective of becoming a fully integrated pharma company.

Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

Retrieved on: 
Thursday, October 20, 2022
U.S. Securities and Exchange Commission, Pharmacy, McGill, RNA transfection, SEC, Growth, NASDAQ, Patient, University, Squamous cell carcinoma, Research, Breast cancer, Health Canada, Company, Acquisition, Sunlight, OBI Pharma, Inc., CEO, Combined small-cell lung carcinoma, General Hospital, GLOBE, COVID-19, Pancreatic cancer, Foot, Risk, Leadership, Generic drug, Pharmaceutical industry, Greater Montreal

The addition of Nora Pharma allows Sunshine Biopharma to expand its operations into the area of generic prescription drugs and biosimilars.

Key Points: 
  • The addition of Nora Pharma allows Sunshine Biopharma to expand its operations into the area of generic prescription drugs and biosimilars.
  • The purchase price of $30,000,000 Canadian (approximately $21,900,000 US) was paid by cash, Sunshine Biopharma common stock, and an earn-out amount.
  • The strategic acquisition of Nora Pharma significantly expands our revenue stream and is expected to generate multi-year top-line and bottom-line growth going forward, said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
  • Dr. Slilaty added, Nora Pharma will operate as a subsidiary of Sunshine Biopharma, with Mr. Chamoun as president.

Sunshine Biopharma Files Its Second Quarter Report With the SEC

Retrieved on: 
Thursday, August 4, 2022
Combined small-cell lung carcinoma, Securities Act of 1933, Security (finance), Breast cancer, COVID-19, Pancreatic cancer, University of Arizona, RNA, General Hospital, Common stock, Securities Exchange Act of 1934, Risk, Patient, Company, University, U.S. Securities and Exchange Commission, Safety, University of Illinois at Chicago, Research, Report, Chicago, Pharmacokinetics, Nasdaq, GLOBE, Severe acute respiratory syndrome coronavirus 2, SEC, Squamous cell carcinoma, RNA transfection, Coronavirus, McGill, NASDAQ, Pharmaceutical industry

The Report shows that the Company had Cash & Cash Equivalents of $41,727,775 as of June 30, 2022, compared to $2,045,167 as of December 31, 2021.

Key Points: 
  • The Report shows that the Company had Cash & Cash Equivalents of $41,727,775 as of June 30, 2022, compared to $2,045,167 as of December 31, 2021.
  • Sunshine Biopharmas CFO, Camille Sebaaly, stated, We are very pleased with the progress of our Company as a whole.
  • Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
  • The Company's SEC filings can be obtained free of charge on the SEC's website at www.sec.gov.

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

Retrieved on: 
Thursday, July 28, 2022
Online, Severe acute respiratory syndrome coronavirus 2, University, College of Medicine, GLOBE, Omicron, Pharmacology, Southwestern United States, College, McGill, U.S. Securities and Exchange Commission, Drug discovery, Doctor of Philosophy, Student, Medicine, Neurodegeneration, CEO, SEC, Research, Addiction, Nursing school, Toxicology, Squamous cell carcinoma, Immune system, Safety, COVID-19, Degenerative disease, Vaccine, NASDAQ, General Hospital, Cancer, Pancreatic cancer, Company, Pharmacokinetics, Pain, Faculty, Measles, Growth, Risk, Contract, Disease, Combined small-cell lung carcinoma, Public health, Breast cancer, Pharmaceutical industry, Pharmacy

At the University of Arizona Health Sciences, Gregory Thatcher, PhD, a professor of pharmacology and toxicology and the R. Ken and Donna Coit Endowed Chair of Drug Discovery, is leading the research effort that is progressing as planned.

Key Points: 
  • At the University of Arizona Health Sciences, Gregory Thatcher, PhD, a professor of pharmacology and toxicology and the R. Ken and Donna Coit Endowed Chair of Drug Discovery, is leading the research effort that is progressing as planned.
  • Located on campuses in Tucson, Phoenix and Gilbert, Arizona, the University of Arizona Health Sciences is one of the top-ranked academic medical centers in the southwestern United States.
  • In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.
  • Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.

Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market

Retrieved on: 
Thursday, April 28, 2022
Mouse, U.S. Securities and Exchange Commission, Pharmacokinetics, Combined small-cell lung carcinoma, Exclusive, Securities Exchange Act of 1934, McGill, Sale, University, GLOBE, University of Arizona, COVID-19, Risk, Securities Act of 1933, Company, Squamous cell carcinoma, Pancreatic cancer, Exercise, Security (finance), Research, NASDAQ, General Hospital, SEC, Breast cancer, Severe acute respiratory syndrome coronavirus 2, Safety, Pharmaceutical industry, Nasdaq

The warrants have a term equal to five years from the issuance date.

Key Points: 
  • The warrants have a term equal to five years from the issuance date.
  • Aegis Capital Corp. acted as the Exclusive Placement Agent in connection with the offering.
  • Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill Universitys Jewish General Hospital in Montreal, Canada.
  • The Company's SEC filings can be obtained free of charge on the SEC's website at www.sec.gov.

Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market

Retrieved on: 
Tuesday, April 26, 2022
Breast cancer, Pancreatic cancer, Pharmacokinetics, U.S. Securities and Exchange Commission, Combined small-cell lung carcinoma, COVID-19, Security (finance), Risk, NASDAQ, Research, Squamous cell carcinoma, GLOBE, Sale, Securities Act of 1933, University, Securities Exchange Act of 1934, General Hospital, Exclusive, Company, University of Arizona, SEC, Safety, Mouse, McGill, Exercise, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Nasdaq

In connection with the offering, the Company will issue 4,862,845 units and pre-funded units at a purchase price of $4.01 per unit, priced at-the-market under Nasdaq rules.

Key Points: 
  • In connection with the offering, the Company will issue 4,862,845 units and pre-funded units at a purchase price of $4.01 per unit, priced at-the-market under Nasdaq rules.
  • The offering is expected to close on or about April 28, 2022, subject to the satisfaction of customary closing conditions.
  • Aegis Capital Corp. is acting as the Exclusive Placement Agent in connection with the offering.
  • In addition to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development of Adva-27a, a unique anticancer compound.

Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells

Retrieved on: 
Monday, April 25, 2022
Patent, CEO, Breast cancer, Pancreatic cancer, Pharmacokinetics, Combined small-cell lung carcinoma, Culture, COVID-19, Risk, NASDAQ, Research, Squamous cell carcinoma, GLOBE, Securities Act of 1933, Patient, University, Securities Exchange Act of 1934, General Hospital, Company, University of Arizona, SEC, Safety, Mouse, RNA transfection, McGill, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry

The patent application contains composition and utility subject matter pertaining to the structure and sequence of the relevant mRNA molecules.

Key Points: 
  • The patent application contains composition and utility subject matter pertaining to the structure and sequence of the relevant mRNA molecules.
  • The cytotoxic effects of the subject mRNA molecules were tested on different cancer cells including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2).
  • In contrast to cancer cells, the mRNA molecules had little cytotoxic effects on non-transformed (normal) human cells (HMEC cells).
  • Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells.

Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells

Retrieved on: 
Tuesday, April 5, 2022
Company, Pancreatic cancer, NASDAQ, Patent, University of Arizona, Risk, General Hospital, Pharmacokinetics, Culture, Combined small-cell lung carcinoma, Mouse, Research, SEC, CEO, Severe acute respiratory syndrome coronavirus 2, University, Safety, Securities Exchange Act of 1934, RNA transfection, Securities Act of 1933, Squamous cell carcinoma, Breast cancer, COVID-19, GLOBE, McGill, Patient, Toxicity, Pharmaceutical industry

The cytotoxicity tests were performed on a variety of cancer cells including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2).

Key Points: 
  • The cytotoxicity tests were performed on a variety of cancer cells including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2).
  • Toxicity studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little or no cytotoxic effects.
  • These new mRNA molecules are readily adaptable for delivery into patients using the mRNA vaccine technology.
  • Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells.